DK1536783T3 - Faste formuleringer, der omfatter en indolinonforbindelse - Google Patents

Faste formuleringer, der omfatter en indolinonforbindelse

Info

Publication number: DK1536783T3
Authority: DK; Denmark
Prior art keywords: solid formulations; indolinone compound; indolinone; compound; formulations
Prior art date: 2002-09-10

Application number

DK03772489T

Other languages

English (en)

Inventor

Paolo Gatti

Original Assignee

Pfizer Italia Srl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-10

Filing date

2003-09-10

Publication date

2008-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994326&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1536783(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-10 Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl

2008-10-13 Application granted granted Critical

2008-10-13 Publication of DK1536783T3 publication Critical patent/DK1536783T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

DK03772489T 2002-09-10 2003-09-10 Faste formuleringer, der omfatter en indolinonforbindelse DK1536783T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US42113302P	2002-09-10	2002-09-10
PCT/IB2003/005293 WO2004024127A2 (en)	2002-09-10	2003-09-10	Solid formulations comprising an indolinone compound

Publications (1)

Publication Number	Publication Date
DK1536783T3 true DK1536783T3 (da)	2008-10-13

Family

ID=31994326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03772489T DK1536783T3 (da)	2002-09-10	2003-09-10	Faste formuleringer, der omfatter en indolinonforbindelse

Country Status (31)

Country	Link
US (1)	US20040229930A1 (da)
EP (1)	EP1536783B2 (da)
JP (1)	JP2006503032A (da)
KR (1)	KR20050059170A (da)
CN (1)	CN1688304A (da)
AR (1)	AR041193A1 (da)
AT (1)	ATE403425T1 (da)
AU (1)	AU2003280108B2 (da)
BR (1)	BR0314182A (da)
CA (1)	CA2498415C (da)
DE (1)	DE60322720D1 (da)
DK (1)	DK1536783T3 (da)
DO (1)	DOP2003000708A (da)
ES (1)	ES2309363T5 (da)
GT (1)	GT200300193A (da)
HN (1)	HN2003000272A (da)
MX (1)	MXPA05002690A (da)
MY (1)	MY136767A (da)
NL (1)	NL1024261C (da)
NO (1)	NO20051670L (da)
NZ (1)	NZ538636A (da)
PA (1)	PA8581801A1 (da)
PE (1)	PE20040989A1 (da)
PL (1)	PL375978A1 (da)
PT (1)	PT1536783E (da)
RU (1)	RU2005110663A (da)
SI (1)	SI1536783T1 (da)
TW (1)	TW200418836A (da)
UY (1)	UY27969A1 (da)
WO (1)	WO2004024127A2 (da)
ZA (1)	ZA200501897B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4933259B2 (ja)	2003-10-02	2012-05-16	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	ピロール置換インドリノン化合物の塩および多形
WO2007034327A1 (en) *	2005-09-20	2007-03-29	Pfizer Products Inc.	Dosage forms and methods of treatment using a tyrosine kinase inhibitor
CN101007801A (zh) *	2006-01-27	2007-08-01	上海恒瑞医药有限公司	吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
WO2008024044A1 (en) *	2006-08-21	2008-02-28	Astrazeneca Ab	Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) *	2006-08-21	2015-05-01	Astrazeneca Ab	適合口服且包含***并[4,5-d]嘧啶衍生物之組合物
US20090004213A1 (en)	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
CA2699306A1 (en) *	2007-11-21	2009-05-28	Teva Pharmaceutical Industries Ltd.	Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
EP2090306A1 (en)	2008-02-13	2009-08-19	Ratiopharm GmbH	Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en)	2008-04-29	2009-11-04	Ratiopharm GmbH	Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2240174A1 (en) *	2008-02-13	2010-10-20	Ratiopharm GmbH	Pharmaceutical compositions comprising n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2138167A1 (en) *	2008-06-24	2009-12-30	ratiopharm GmbH	Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
KR20110036588A (ko)	2008-07-24	2011-04-07	테바 파마슈티컬 인더스트리즈 리미티드	수니티닙 아세테이트 및 이의 다형을 통한 수니티닙 말레이트의 제조 방법
CA2704448A1 (en) *	2008-09-30	2010-04-08	Teva Pharmaceutical Industries Ltd.	Amorphous compositions of sunitinib base and l-malic acid
WO2012042421A1 (en)	2010-09-29	2012-04-05	Pfizer Inc.	Method of treating abnormal cell growth
CN103301116A (zh) *	2012-03-16	2013-09-18	大鹏药品工业株式会社	口服医药组合物
RU2609651C2 (ru)	2012-05-04	2017-02-02	Пфайзер Инк.	Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
CN104069076A (zh) *	2013-03-29	2014-10-01	浙江九洲药业股份有限公司	一种无定型的舒尼替尼与pvp的组合物
MY182168A (en)	2013-11-01	2021-01-18	Pfizer	Vectors for expression of prostate-associated antigens
WO2015110952A1 (en)	2014-01-21	2015-07-30	Wockhardt Limited	Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104829596B (zh) *	2014-02-10	2017-02-01	石家庄以岭药业股份有限公司	吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
EP3539536A1 (en)	2018-03-15	2019-09-18	MH10 Spolka z ograniczona odpowiedzialnoscia	A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
SG11202107438WA (en) *	2019-01-09	2021-08-30	Celgene Corp	Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
US20230355581A1 (en) *	2020-07-02	2023-11-09	The Board of Regents of the Unversity of Texas System	Methods of treatment for melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4609675A (en) *	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US6077533A (en) *	1994-05-25	2000-06-20	Purdue Pharma L.P.	Powder-layered oral dosage forms
PT1233943E (pt) *	1999-11-24	2011-09-01	Sugen Inc	Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
DE19956598A1 (de) *	1999-11-25	2001-06-13	Bosch Gmbh Robert	Ventil zum Steuern von Flüssigkeiten
BRPI0108394B8 (pt) *	2000-02-15	2021-05-25	Upjohn Co	inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
DK3168218T3 (da) *	2001-08-15	2019-01-14	Pharmacia & Upjohn Co Llc	Krystal omfattende et l-æblesyresalt af n-[2-(diethylamino)ethyl]-5-[(5-fluor-1,2-dihydro-2-oxo-3h-indol-3-yliden)methyl]-2,4-dimethyl-1h-pyrrol-3-carboxamid til anvendelse som et medikament
TWI259081B (en) †	2001-10-26	2006-08-01	Sugen Inc	Treatment of acute myeloid leukemia with indolinone compounds

2003
- 2003-09-09 TW TW092124905A patent/TW200418836A/zh unknown
- 2003-09-09 HN HN2003000272A patent/HN2003000272A/es unknown
- 2003-09-10 EP EP03772489A patent/EP1536783B2/en not_active Expired - Lifetime
- 2003-09-10 AR ARP030103269A patent/AR041193A1/es not_active Application Discontinuation
- 2003-09-10 MX MXPA05002690A patent/MXPA05002690A/es not_active Application Discontinuation
- 2003-09-10 AT AT03772489T patent/ATE403425T1/de not_active IP Right Cessation
- 2003-09-10 ES ES03772489T patent/ES2309363T5/es not_active Expired - Lifetime
- 2003-09-10 PL PL03375978A patent/PL375978A1/xx not_active Application Discontinuation
- 2003-09-10 PA PA20038581801A patent/PA8581801A1/es unknown
- 2003-09-10 SI SI200331328T patent/SI1536783T1/sl unknown
- 2003-09-10 NZ NZ538636A patent/NZ538636A/en unknown
- 2003-09-10 GT GT200300193A patent/GT200300193A/es unknown
- 2003-09-10 PE PE2003000913A patent/PE20040989A1/es not_active Application Discontinuation
- 2003-09-10 RU RU2005110663/15A patent/RU2005110663A/ru not_active Application Discontinuation
- 2003-09-10 JP JP2004535803A patent/JP2006503032A/ja active Pending
- 2003-09-10 CN CNA038238500A patent/CN1688304A/zh active Pending
- 2003-09-10 MY MYPI20033418A patent/MY136767A/en unknown
- 2003-09-10 NL NL1024261A patent/NL1024261C/nl not_active IP Right Cessation
- 2003-09-10 WO PCT/IB2003/005293 patent/WO2004024127A2/en active IP Right Grant
- 2003-09-10 DO DO2003000708A patent/DOP2003000708A/es unknown
- 2003-09-10 DK DK03772489T patent/DK1536783T3/da active
- 2003-09-10 PT PT03772489T patent/PT1536783E/pt unknown
- 2003-09-10 BR BR0314182-9A patent/BR0314182A/pt not_active IP Right Cessation
- 2003-09-10 US US10/658,801 patent/US20040229930A1/en not_active Abandoned
- 2003-09-10 CA CA002498415A patent/CA2498415C/en not_active Expired - Lifetime
- 2003-09-10 UY UY27969A patent/UY27969A1/es not_active IP Right Cessation
- 2003-09-10 AU AU2003280108A patent/AU2003280108B2/en not_active Ceased
- 2003-09-10 KR KR1020057004142A patent/KR20050059170A/ko not_active Application Discontinuation
- 2003-09-10 DE DE60322720T patent/DE60322720D1/de not_active Expired - Lifetime
2005
- 2005-03-04 ZA ZA200501897A patent/ZA200501897B/en unknown
- 2005-04-04 NO NO20051670A patent/NO20051670L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2006503032A (ja)	2006-01-26
DOP2003000708A (es)	2004-03-31
CA2498415A1 (en)	2004-03-25
TW200418836A (en)	2004-10-01
UY27969A1 (es)	2004-04-30
RU2005110663A (ru)	2005-09-10
AU2003280108B2 (en)	2007-04-05
ATE403425T1 (de)	2008-08-15
NZ538636A (en)	2006-04-28
PA8581801A1 (es)	2005-02-04
AU2003280108A1 (en)	2004-04-30
NL1024261A1 (nl)	2004-03-11
KR20050059170A (ko)	2005-06-17
EP1536783B2 (en)	2011-08-24
EP1536783A2 (en)	2005-06-08
PE20040989A1 (es)	2004-12-28
NO20051670L (no)	2005-04-04
AR041193A1 (es)	2005-05-04
GT200300193A (es)	2004-04-29
MXPA05002690A (es)	2005-05-05
SI1536783T1 (sl)	2008-12-31
CA2498415C (en)	2007-05-29
WO2004024127A2 (en)	2004-03-25
ZA200501897B (en)	2005-09-07
ES2309363T3 (es)	2008-12-16
ES2309363T5 (es)	2011-12-07
CN1688304A (zh)	2005-10-26
WO2004024127A3 (en)	2004-06-03
DE60322720D1 (de)	2008-09-18
EP1536783B1 (en)	2008-08-06
BR0314182A (pt)	2005-08-09
HN2003000272A (es)	2008-07-29
PT1536783E (pt)	2008-10-10
NL1024261C (nl)	2010-04-06
US20040229930A1 (en)	2004-11-18
MY136767A (en)	2008-11-28
PL375978A1 (en)	2005-12-12

Publication	Publication Date	Title
DK1536783T3 (da)	2008-10-13	Faste formuleringer, der omfatter en indolinonforbindelse
DE60336314D1 (de)	2011-04-21	Substituierte indole
DE60225563D1 (de)	2008-04-24	4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
DK1545467T3 (da)	2007-11-05	Faste farmaceutiske formuleringer omfattende telmisartan
DE60318890D1 (de)	2008-03-13	Mandelsäure derivate
DE602004006169D1 (de)	2007-06-06	Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
NO20052239D0 (no)	2005-05-06	Fast preparat
DE602004024770D1 (de)	2010-02-04	Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
IS7793A (is)	2005-04-11	Nýtt efnasamband
IS7794A (is)	2005-04-11	Nýtt efnasamband
DE60305332D1 (de)	2006-06-22	IMIDAZOi1,2-AöPYRIDINE
NO20051500D0 (no)	2005-03-21	Substituerte heterocyklylpyrimidiner.
DE60324703D1 (de)	2008-12-24	Barbitursäure derivaten.
ES1051856Y (es)	2003-02-01	Burlete perfeccionado.
NO20044405L (no)	2004-10-15	Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
ES1049838Y (es)	2002-05-16	Calzado perfeccionado.
ES1055317Y (es)	2004-03-01	Escenario autotransportable.
ES1050965Y (es)	2002-10-01	Decantador perfeccionado.
ES1051803Y (es)	2003-02-01	Andamio perfeccionado.
ES1049590Y (es)	2002-04-16	Cenicero ambientador perfeccionado.
ES1048757Y (es)	2002-02-01	Calzado perfeccionado.
ES1051713Y (es)	2003-01-16	Sobre-nota perfeccionado.
ES1051515Y (es)	2002-12-01	Estuche perfeccionado.
ES1051560Y (es)	2002-12-01	Avisador perfeccionado.
ES1052103Y (es)	2003-03-01	Cartera-monedero perfeccionada.